Vorinostat

ATC Code L01XH01

Vorinostat

Definition

A synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety to chelate zinc ion located in the catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Hyperacetylation of histone proteins results in the upregulation of the cyclin-dependant kinase p21, followed by G1 arrest. Hyperacetylation of non-histone proteins such as tumor suppressor p53, alpha tubulin, and heat-shock protein 90 produces additional anti-proliferative effects. This agent also induces apoptosis and sensitizes tumor cells to cell death processes. Vorinostat crosses the blood-brain barrier.

Also known as L-001079038, MSK-390, N-Hydroxy-N'-phenyloctanediamide, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, VORINOSTAT, Zolinza — per NCIT

Also identified as

Indications

Disease Relation Source
Primary cutaneous T-cell non-Hodgkin lymphoma may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Lymphoid system may treat a disease of this organ DERIVED · CC BY 4.0
Skin of body may treat a disease of this organ DERIVED · CC BY 4.0

2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.